Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41582-021-00474-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expanding Beyond Genetic Subtypes in B-Cell Acute Lymphoblastic Leukemia: A Pathway-Based Stratification of Patients for Precision Oncology.
OMICS
September 2024
Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Istanbul Bilgi University, Istanbul, Turkiye.
Precision oncology promises individually tailored drugs and clinical care for patients with cancer: That is, "the right drug, for the right patient, at the right dose, and at the right time." Although stratification of the risk for treatment resistance and toxicity is key to precision oncology, there are multiple ways in which such stratification can be achieved, for example, genetic, functional pathway based, among others. Moving toward precision oncology is sorely needed in the case of acute lymphoblastic leukemia (ALL) wherein adult patients display survival rates ranging from 30% to 70%.
View Article and Find Full Text PDFGenetic variability in the glucocorticoid pathway and treatment outcomes in hospitalized patients with COVID-19: a pilot study.
Front Pharmacol
July 2024
Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Article Synopsis
- - Corticosteroids like dexamethasone are commonly used to treat severe COVID-19, but genetic variations in patients may impact how well they respond to treatment and their overall outcomes.
- - A study of 107 hospitalized COVID-19 patients identified specific genetic polymorphisms related to the glucocorticoid receptor that influenced disease severity; notably, the rs35599367 variant was linked to a higher risk of critical illness and worse outcomes.
- - Other polymorphisms, such as rs6198 and rs33388, were associated with variations in treatment duration and hospitalization time, highlighting the importance of genetic factors in managing COVID-19 treatment responses.
Protocol for performing metabolic pathway-based subtyping of breast tumors.
STAR Protoc
September 2024
Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address:
Article Synopsis
- - The protocol focuses on analyzing the metabolic landscape of breast tumors to help classify patients based on their metabolic profiles.
- - It involves examining 1,454 metabolic genes tied to 90 pathways and utilizing an algorithm to determine the deregulation of these pathways in tumor samples.
- - The process includes clustering analysis to find metabolic subtypes and implementing machine learning to create distinct signatures for each subtype.
Postsurgical Pain Risk Stratification to Enhance Pain Management Workflow in Adult Patients: Design, Implementation, and Pilot Evaluation.
JMIR Perioper Med
July 2024
Department of Anesthesiology, Pharmacology & Therapeutics, The University of British Columbia, Vancouver, BC, Canada.
Background: Exposure to opioids after surgery is the initial contact for some people who develop chronic opioid use disorder. Hence, effective postoperative pain management, with less reliance on opioids, is critical. The Perioperative Opioid Quality Improvement (POQI) program developed (1) a digital health platform leveraging patient-survey-reported risk factors and (2) a postsurgical pain risk stratification algorithm to personalize perioperative care by integrating several commercially available digital health solutions into a combined platform.
View Article and Find Full Text PDFMetabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes.
Hematol Oncol
July 2024
National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China.
Article Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is a complex disease that needs tailored treatment based on individual patient characteristics and genetic factors.
- Researchers focused on metabolic processes and their impact on DLBCL, outlining how metabolism affects the tumor environment and immune cell behavior.
- By analyzing 1660 genes across various metabolic pathways, they created metabolic clusters (MECs), which showed different survival rates and provided insights for improving DLBCL treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!